Who Optimizes SG&A Costs Better? AstraZeneca PLC or Pfizer Inc.

AstraZeneca vs. Pfizer: SG&A Cost Strategies Unveiled

__timestamp	AstraZeneca PLC	Pfizer Inc.
Wednesday, January 1, 2014	13324000000	14097000000
Thursday, January 1, 2015	11451000000	14809000000
Friday, January 1, 2016	9739000000	14837000000
Sunday, January 1, 2017	10543000000	14784000000
Monday, January 1, 2018	10362000000	14455000000
Tuesday, January 1, 2019	11848000000	14350000000
Wednesday, January 1, 2020	11693000000	11615000000
Friday, January 1, 2021	15680000000	12703000000
Saturday, January 1, 2022	18955000000	13677000000
Sunday, January 1, 2023	18025000000	14771000000
Monday, January 1, 2024	20532000000	14730000000

Unlocking the unknown

Optimizing SG&A Costs: AstraZeneca vs. Pfizer

In the competitive pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. From 2014 to 2023, AstraZeneca PLC and Pfizer Inc. have shown distinct strategies in optimizing these costs. AstraZeneca's SG&A expenses fluctuated, peaking in 2022 with a 95% increase from its 2016 low. Meanwhile, Pfizer maintained a more stable trajectory, with expenses peaking in 2016 and showing a 1% decrease by 2023.

AstraZeneca's aggressive cost management in recent years suggests a strategic pivot, possibly to support its expanding product pipeline. In contrast, Pfizer's consistent SG&A spending reflects its established market position and focus on operational efficiency. This analysis highlights the dynamic approaches of two pharmaceutical giants in navigating financial challenges over the past decade.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025